CMTM6和CMTM4在肿瘤发生、发展及预后中的作用  

Role of CMTM6 and CMTM4 protein in tumorigenesis,development and prognosis

作　　者：马明珠 高晓玲[2] Ma Mingzhu;Gao Xiaoling(Second Clinical Medical College of Shanxi Medical University,Taiyuan 030000,China;Department of Respiratory and Critical Care Medicine,Second Hospital of Shanxi Medical University,Taiyuan 030000,China)

机构地区：[1]山西医科大学第二临床医学院,太原030000 [2]山西医科大学第二医院呼吸与危重症医学科,太原030000

出　　处：《国际肿瘤学杂志》2024年第11期706-711,共6页Journal of International Oncology

基　　金：国家自然科学基金(82370091);山西省卫生健康委员会科技兴医创新计划(2023XM001);山西省科技成果转化引导专项(202204021301068);山西省高等教育“百亿工程”科技引导专项(BYJL029)。

摘　　要：含有MARVEL跨膜结构域的趋化样因子基因(CMTM)家族在肿瘤发生、发展、转移和耐药方面起着至关重要的作用。CMTM6和CMTM4是调节程序性死亡受体配体1(PD-L1)稳定性的关键蛋白,尤其在肿瘤免疫治疗耐药性中发挥着重要作用。目前,CMTM6和CMTM4与肿瘤相关的详尽分子机制尚未完全明确。深入研究CMTM4和CMTM6在肿瘤中的表达、生物学作用以及调控机制将为肿瘤的诊断、治疗以及预测预后等方面提供新的思路和靶点。The CKLF-like MARVEL transmembrane domain containing family of genes(CMTM)family plays a crucial role in tumorigenesis,development,metastasis,and drug resistance.CMTM6 and CMTM4 are key proteins that regulate the stability of programmed death-ligand 1(PD-L1)and play an important role in tumor immunotherapy resistance in particular.At present,the detailed molecular mechanisms linking CMTM6 and CMTM4 with tumors have not been fully understood.In-depth study of the expression,biological role and regulatory mechanism of CMTM4 and CMTM6 in tumors will provide new ideas and targets for the diagnosis,treatment and prediction of prognosis of tumors.

关 键 词：CMTM6 CMTM4 肿瘤 耐药性 

分 类 号：R73[医药卫生—肿瘤]